{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:08:07Z","timestamp":1791288487729,"version":"4.3.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jgar.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T16:53:53Z","timestamp":1707324833000},"page":"11-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Global distribution of heterogeneous vancomycin-intermediate Staphylococcus aureus strains (1997\u20132021): a systematic review and meta-analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Masoud","family":"Keikha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9899-2885","authenticated-orcid":false,"given":"Mohsen","family":"Karbalaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.02.002_bib0001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.00036-07","article-title":"From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis","volume":"21","author":"Frank","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2024.02.002_bib0002","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0140-6736(09)61999-1","article-title":"Community-associated meticillin-resistant Staphylococcus aureus","volume":"375","author":"DeLeo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2024.02.002_bib0003","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1473-3099(01)00091-3","article-title":"Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance","volume":"1","author":"Hiramatsu","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0004","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0005","unstructured":"Wayne P. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: 20th informational supplement. CLSI document M100-S20. 2010."},{"key":"10.1016\/j.jgar.2024.02.002_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/14787210.7.1.1","article-title":"hVISA\/VISA: diagnostic and therapeutic problems","volume":"7","author":"Szab\u00f3","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2024.02.002_bib0007","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/513203","article-title":"The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus","volume":"44","author":"Tenover","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0008","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","article-title":"Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility","volume":"40","author":"Hiramatsu","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00000446-200211000-00015","article-title":"First reported case of VRSA in the United States: an alarming development in microbial resistance","volume":"102","author":"Goldrick","year":"2002","journal-title":"Am J Nurs"},{"key":"10.1016\/j.jgar.2024.02.002_bib0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/317542","article-title":"Vancomycin-intermediate and-resistant Staphylococcus aureus: what the infectious disease specialist needs to know","volume":"32","author":"Weinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0011","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0002-9343(98)00149-1","article-title":"The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan","volume":"104","author":"Hiramatsu","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.jgar.2024.02.002_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200161010-00001","article-title":"Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance","volume":"61","author":"Rybak","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2024.02.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2021.102552","article-title":"Antimicrobial photodynamic therapy (aPDT) against vancomycin resistant Staphylococcus aureus (VRSA) biofilm disruption: a putative role of phagocytosis in infection control","volume":"36","author":"Akhtar","year":"2021","journal-title":"Photodiagnosis and Photodynamic Therapy"},{"key":"10.1016\/j.jgar.2024.02.002_bib0014","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/AAC.01133-10","article-title":"Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates","volume":"55","author":"van Hal","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0015","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.ijid.2012.08.005","article-title":"High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis","volume":"17","author":"Jacob","year":"2013","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0016","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"Van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0017","article-title":"Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2024.02.002_bib0018","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1086\/491713","article-title":"Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy","volume":"42","author":"Sakoulas","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0019","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.micinf.2019.04.003","article-title":"VraSR has an important role in immune evasion of Staphylococcus aureus with low level vancomycin resistance","volume":"21","author":"Gao","year":"2019","journal-title":"Microbes Infect"},{"key":"10.1016\/j.jgar.2024.02.002_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IDR.S393415","article-title":"Heterogeneous vancomycin intermediate Staphylococcus aureus infections in diabetic and non-diabetic patients: a hospital-based comparative study","volume":"16","author":"Sreejisha","year":"2023","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2024.02.002_bib0021","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1007\/s00284-020-02123-y","article-title":"Etest methods for screening heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) strains","volume":"77","author":"Lee","year":"2020","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.jgar.2024.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(97)07324-8","article-title":"Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin","volume":"350","author":"Hiramatsu","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2024.02.002_bib0024","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/jac\/43.6.846","article-title":"Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the D\u00fcsseldorf area","volume":"43","author":"Geisel","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0025","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/jac\/43.5.729","article-title":"Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus","volume":"43","author":"Kantzanou","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0026","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s100960050340","article-title":"Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds","volume":"18","author":"Schmitz","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0027","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(99)01017-X","article-title":"Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin","volume":"353","author":"Ariza","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2024.02.002_bib0028","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s100960050380","article-title":"Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany","volume":"18","author":"Bierbaum","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0029","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/520429","article-title":"Bacteremia caused by staphylococci with inducible vancomycin heteroresistance","volume":"29","author":"Wong","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0030","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1128\/JCM.38.2.866-869.2000","article-title":"Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital","volume":"38","author":"Marchese","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0031","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1128\/JCM.38.10.3879-3881.2000","article-title":"Vancomycin-intermediate Staphylococcus aureus in Korea","volume":"38","author":"Kim","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0032","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/46.4.639-a","article-title":"Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus","volume":"46","author":"Aucken","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0033","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1128\/JCM.39.12.4445-4451.2001","article-title":"Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals","volume":"39","author":"Ike","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0034","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1198-743x.2001.00256.x","article-title":"Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals","volume":"7","author":"Reverdy","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.02.002_bib0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/47.4.399","article-title":"A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital","volume":"47","author":"Wootton","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0036","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1128\/JCM.39.2.591-595.2001","article-title":"First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand","volume":"39","author":"Trakulsomboon","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0037","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/JCM.40.4.1376-1380.2002","article-title":"Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea","volume":"40","author":"Kim","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0038","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jac\/dkf142","article-title":"Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features","volume":"50","author":"Denis","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0039","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1128\/JCM.40.6.2249-2250.2002","article-title":"Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections","volume":"40","author":"Tallent","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0040","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1128\/JCM.41.6.2279-2281.2003","article-title":"Nationwide surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in Korea","volume":"41","author":"Kim","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0041","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1128\/JCM.41.11.5147-5152.2003","article-title":"Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients","volume":"41","author":"Bert","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0042","first-page":"216","article-title":"Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002","volume":"55","author":"M\u0142ynarczyk","year":"2003","journal-title":"Medycyna Do\u015bwiadczalna"},{"key":"10.1016\/j.jgar.2024.02.002_bib0043","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.patbio.2004.07.016","article-title":"Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital","volume":"52","author":"Pierard","year":"2004","journal-title":"Pathologie Biologie"},{"key":"10.1016\/j.jgar.2024.02.002_bib0044","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1128\/AAC.48.12.4926-4928.2004","article-title":"Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin","volume":"48","author":"Song","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0045","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1086\/383036","article-title":"Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia","volume":"38","author":"Khosrovaneh","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0046","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","author":"Charles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0047","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijantimicag.2005.04.007","article-title":"Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents","volume":"26","author":"Hsueh","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.02.002_bib0048","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1469-0691.2004.01060.x","article-title":"Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals","volume":"11","author":"Nonhoff","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.02.002_bib0049","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1128\/JCM.43.5.2494-2496.2005","article-title":"Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus","volume":"43","author":"Plipat","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0050","first-page":"1","article-title":"Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital","volume":"5","author":"Nakipoglu","year":"2005","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0051","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/jac\/dki272","article-title":"Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital","volume":"56","author":"Sancak","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0052","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1086\/429906","article-title":"Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area","volume":"40","author":"Egu\u00eda","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0053","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1086\/498898","article-title":"Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit","volume":"42","author":"de Lassence","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0054","first-page":"144","article-title":"Resistance of Staphyiococcus aureus to vancomycin in Zarqa","volume":"22","author":"Bataineh","year":"2006","journal-title":"Jordan. Pakistan J Med Sci"},{"key":"10.1016\/j.jgar.2024.02.002_bib0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/jac\/dki413","article-title":"A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital","volume":"57","author":"Garnier","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0056","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1128\/JCM.01262-06","article-title":"Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center","volume":"45","author":"Maor","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-0711-6-13","article-title":"Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections","volume":"6","author":"Neoh","year":"2007","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2024.02.002_bib0058","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1128\/JCM.02437-06","article-title":"Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico","volume":"45","author":"Delgado","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0059","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1128\/JCM.00836-07","article-title":"Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus","volume":"45","author":"Fitzgibbon","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0060","first-page":"176","article-title":"Modified PAP method to detect heteroresistance to vancomycin among methicillin resistant Staphylococcus aureus isolates at a tertiary care hospital","volume":"26","author":"Iyer","year":"2008","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0061","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.00582-08","article-title":"Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)","volume":"46","author":"Rybak","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0062","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1128\/AAC.01073-08","article-title":"Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center","volume":"52","author":"Kosowska-Shick","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0063","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10096-009-0741-5","article-title":"Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore","volume":"28","author":"Fong","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0064","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1128\/JCM.02135-08","article-title":"Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years","volume":"47","author":"Musta","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0065","article-title":"Clinical and bacteriologic characteristics of a 5-year cohort of MRSA patients at a large U.S. metropolitan hospital","volume":"15","author":"Pastagia","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.02.002_bib0066","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1128\/AAC.00206-09","article-title":"Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China","volume":"53","author":"Sun","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0067","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1128\/JCM.01184-09","article-title":"Lack of heteroresistance among Staphylococcus aureus isolates with vancomycin MICs of 2 micrograms per milliliter by automated testing","volume":"47","author":"Satola","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0068","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1086\/596629","article-title":"Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia","volume":"199","author":"Maor","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0069","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1128\/JCM.01749-08","article-title":"The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand","volume":"47","author":"Lulitanond","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0070","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1128\/AAC.01365-08","article-title":"Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA","volume":"53","author":"Horne","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0071","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/JCM.00539-09","article-title":"Molecular and phenotypic characteristics of methicillin-resistant and vancomycin-intermediate Staphylococcus aureus isolates from patients with septic arthritis","volume":"47","author":"Wang","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0072","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/jac\/dkp319","article-title":"Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals","volume":"64","author":"Sader","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0073","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1086\/606027","article-title":"Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance","volume":"200","author":"Bae","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0074","article-title":"Epidemiology of MRSA bacteraemia and clinical relevance of reduced susceptibility to vancomycin","volume":"15","author":"Lewis","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.02.002_bib0075","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s10096-010-1000-5","article-title":"Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients","volume":"29","author":"Cafiso","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0076","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10096-009-0868-4","article-title":"Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan\u2014SMART program, 2003","volume":"29","author":"Ho","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0077","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/dkq009","article-title":"Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool","volume":"65","author":"Kirby","year":"2010","journal-title":"UK. J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0078","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10096-010-0922-2","article-title":"Vancomycin-heteroresistant phenotype in invasive methicillin-resistant Staphylococcus aureus isolates belonging to spa type 041","volume":"29","author":"Monaco","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0079","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.01316-09","article-title":"Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995\u20132006","volume":"54","author":"Adam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0080","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2010.06.044","article-title":"Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates","volume":"36","author":"Campanile","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.02.002_bib0081","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/jac\/dkq128","article-title":"Antimicrobial susceptibility profiles of Staphylococcus aureus isolated in 2007 from French patients with bloodstream infections: goodbye hVISA, welcome Geraldine?","volume":"65","author":"Gallon","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0082","first-page":"637","article-title":"Nationwide surveillance Study of vancomycin-intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006","volume":"20","author":"Chung","year":"2010","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0083","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/jac\/dkr169","article-title":"Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"66","author":"Khatib","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0084","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijantimicag.2011.06.011","article-title":"Glycopeptide and daptomycin susceptibility and vancomycin heteroresistance of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates from a Greek university hospital","volume":"5","author":"Panagea","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.02.002_bib0085","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1128\/JCM.01435-10","article-title":"Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and agar screening methods","volume":"49","author":"Riederer","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0086","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/JCM.01128-10","article-title":"Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method","volume":"49","author":"Satola","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0087","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1128\/JCM.01719-10","volume":"49","author":"Satola","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0088","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.diagmicrobio.2011.06.010","article-title":"The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC","volume":"71","author":"Chen","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0089","doi-asserted-by":"crossref","first-page":"e21217","DOI":"10.1371\/journal.pone.0021217","article-title":"Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections","volume":"6","author":"van Hal","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2024.02.002_bib0090","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/JCM.00914-10","article-title":"Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates","volume":"49","author":"Pitz","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0091","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1128\/JCM.02302-10","article-title":"Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates","volume":"49","author":"van Hal","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0092","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1128\/JCM.01152-11","article-title":"Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States","volume":"49","author":"Richter","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0093","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/AAC.05024-11","article-title":"Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans","volume":"56","author":"Fink","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0094","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10096-011-1367-y","article-title":"Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis","volume":"31","author":"Campanile","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0095","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1128\/AAC.01139-12","article-title":"Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus","volume":"56","author":"Hafer","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0096","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1086\/663703","article-title":"An outbreak of heterogeneous glycopeptide-intermediate Staphylococcus aureus related to a device source in an intensive care unit","volume":"33","author":"Parer","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0097","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/jac\/dks131","article-title":"Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus","volume":"67","author":"Park","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0098","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jmii.2012.05.004","article-title":"Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan medical center","volume":"45","author":"Lin","year":"2012","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2024.02.002_bib0099","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s10156-011-0330-2","article-title":"Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study","volume":"18","author":"Yamakawa","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0100","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1128\/JCM.06307-11","article-title":"A novel \u03b4-hemolysis screening method for detecting heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate S. aureus","volume":"50","author":"Cafiso","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0101","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.diagmicrobio.2012.08.010","article-title":"In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia","volume":"74","author":"Krause","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0102","first-page":"269","article-title":"The presence of heterogeneous vancomycin-intermediate Staphylococcus aureus (heteroVISA) in a major Malaysian hospital","volume":"67","author":"Ahmad","year":"2012","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.jgar.2024.02.002_bib0103","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.4081\/idr.2012.e20","article-title":"Screening and detection of heterogenous vancomycin intermediate Staphylococcus aureus in Hospital Kuala Lumpur Malaysia, using the glycopeptide resistance detection Etest and population analysis profiling","volume":"4","author":"Ramli","year":"2012","journal-title":"Infect Dis Rep"},{"key":"10.1016\/j.jgar.2024.02.002_bib0104","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijantimicag.2012.07.008","article-title":"Low prevalence of vancomycin heteroresistance among meticillin-resistant Staphylococcus aureus causing bacteraemia in Hong Kong","volume":"6","author":"Ho","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.02.002_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2012.05.582","article-title":"Current status of glycopeptide intermediate and heterogenous glycopeptide intermediate Staphylococcus aureus and their prevailing susceptibility pattern at two tertiary care hospitals of Pakistan","volume":"16","author":"Kaleem","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0106","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3760\/cma.j.issn.0366-6999.20120812","article-title":"Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China","volume":"126","author":"Wang","year":"2013","journal-title":"Chinese Med J"},{"key":"10.1016\/j.jgar.2024.02.002_bib0107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-13-583","article-title":"Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey","volume":"13","author":"Sancak","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0108","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/00365548.2012.723221","article-title":"Presence of both heterogeneous vancomycin-intermediate resistance and \u03b2-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection","volume":"45","author":"Takata","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0109","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijantimicag.2013.07.010","article-title":"High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients","volume":"42","author":"Wang","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.02.002_bib0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3844\/ajidsp.2013.63.70","article-title":"Prevalence of heterogeneous glycopeptide intermediate resistance in methicillin-resistant Staphylococcus aureus","volume":"9","author":"Chaudhary","year":"2013","journal-title":"Am J Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0111","doi-asserted-by":"crossref","first-page":"e73300","DOI":"10.1371\/journal.pone.0073300","article-title":"Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in northeast China","volume":"8","author":"Hu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2024.02.002_bib0112","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1128\/AAC.02820-13","article-title":"Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0113","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.diagmicrobio.2014.04.008","article-title":"Is prediffusion test an alternative to improve accuracy in screening hVISA strains and to detect susceptibility to glycopeptides\/lipopeptides?","volume":"79","author":"de Oliveira Silveira","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0114","first-page":"S7","article-title":"Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Sanprasitthiprasong hospital","volume":"97","author":"Panomket","year":"2014","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.jgar.2024.02.002_bib0115","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jiac.2014.06.012","article-title":"Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011","volume":"20","author":"Hanaki","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0116","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.inf.0000436281.18687.0c","article-title":"No evidence of vancomycin minimal inhibitory concentration creep or heteroresistance identified in pediatric Staphylococcus aureus blood isolates","volume":"33","author":"Goldman","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2024.02.002_bib0117","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/mdr.2014.0190","article-title":"Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital","volume":"21","author":"Di Gregorio","year":"2015","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2024.02.002_bib0118","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mjafi.2014.03.008","article-title":"Heterogeneous vancomycin-intermediate among methicillin resistant Staphylococcus aureus","volume":"71","author":"Chaudhari","year":"2015","journal-title":"Med J Armed Forces India"},{"key":"10.1016\/j.jgar.2024.02.002_bib0119","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijantimicag.2015.03.009","article-title":"Genotype-specific prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in Asian countries","volume":"46","author":"Chung","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.02.002_bib0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.diagmicrobio.2015.03.014","article-title":"Decreasing prevalence of isolates with vancomycin heteroresistance and vancomycin minimum inhibitory concentrations \u22652 mg\/L in methicillin-resistant Staphylococcus aureus over 11 years: potential impact of vancomycin treatment guidelines","volume":"82","author":"Khatib","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0121","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jmii.2014.03.003","article-title":"Molecular characteristics and virulence factors in methicillin-susceptible, resistant, and heterogeneous vancomycin-intermediate Staphylococcus aureus from central-southern China","volume":"48","author":"Liu","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2024.02.002_bib0122","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/JCM.01620-15","article-title":"Screening for intermediately vancomycin-susceptible and vancomycin-heteroresistant Staphylococcus aureus by use of vancomycin-supplemented brain heart infusion agar biplates: defining growth interpretation criteria based on gold standard confirmation","volume":"53","author":"Khatib","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0123","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/mdr.2015.0048","article-title":"The prevalence of vancomycin-intermediate Staphylococcus aureus and heterogeneous VISA among methicillin-resistant strains isolated from pediatric population in a Turkish university hospital","volume":"21","author":"Mirza","year":"2015","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2024.02.002_bib0124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-015-1215-2","article-title":"Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units","volume":"15","author":"Hu","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0125","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.diagmicrobio.2014.12.006","article-title":"Detection of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates using a combination of \u03b4-hemolysis assay and Etest","volume":"81","author":"Chang","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0126","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/mdr.2015.0004","article-title":"Increasing trend of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern India","volume":"21","author":"Singh","year":"2015","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2024.02.002_bib0127","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1128\/AAC.04765-14","article-title":"Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia","volume":"59","author":"Chong","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0128","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.diagmicrobio.2016.09.015","article-title":"Decreasing prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus among blood isolates in Korean hospitals","volume":"86","author":"Kang","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160506","article-title":"Clinical and microbiological characteristics of heteroresistant and vancomycin-intermediate Staphylococcus aureus from bloodstream infections in a Brazilian teaching hospital","volume":"11","author":"da Costa","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2024.02.002_bib0130","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/JCM.02595-15","article-title":"Clinical and molecular characterization of invasive heteroresistant vancomycin-intermediate Staphylococcus aureus infections in Korean hospitals","volume":"54","author":"Kim","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0131","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jmii.2015.07.003","article-title":"Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: a multicenter surveillance study, 2012\u20132013","volume":"49","author":"Huang","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2024.02.002_bib0132","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3343\/alm.2016.36.3.235","article-title":"Prevalence and clinical impact of heterogeneous vancomycin-intermediate Staphylococcus aureus isolated from hospitalized patients","volume":"36","author":"Koh","year":"2016","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.jgar.2024.02.002_bib0133","doi-asserted-by":"crossref","DOI":"10.5812\/jjm.26069","article-title":"Phenotypic characteristics of vancomycin-non-susceptible Staphylococcus aureus","volume":"9","author":"Sirichoat","year":"2016","journal-title":"Jundishapur J Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0134","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jgar.2016.11.006","article-title":"High frequency of SCCmec type V and agr type I among heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in north India","volume":"8","author":"Singh","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.02.002_bib0135","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10096-017-2956-1","article-title":"Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome","volume":"36","author":"Kim","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2609-0","article-title":"Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest\u00ae macromethod among patients with MRSA bloodstream infections: a pilot study","volume":"17","author":"Martirosov","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0137","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jgar.2018.05.001","article-title":"Daptomycin and vancomycin heteroresistance revealed among CC5-SCCmecII MRSA clone and in vitro evaluation of treatment alternatives","volume":"14","author":"Okado","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.02.002_bib0138","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/ijmr.IJMR_1976_17","article-title":"Detection of heterogeneous vancomycin-intermediate Staphylococcus aureus: a preliminary report from south India","volume":"150","author":"Amberpet","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jgar.2024.02.002_bib0139","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1089\/mdr.2019.0178","article-title":"Evaluation of the presence and characterization of vancomycin-intermediate and heterogeneous vancomycin-intermediate level resistance among bloodstream isolates of methicillin-resistant Staphylococcus aureus","volume":"26","author":"Ozmen Capin","year":"2020","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2024.02.002_bib0140","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s42770-020-00384-0","article-title":"Vancomycin MIC and agr dysfunction in invasive MRSA infections in southern Brazil","volume":"51","author":"Rossato","year":"2020","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11274-019-2788-5","article-title":"Attenuated total reflection: Fourier transform infrared spectroscopy for detection of heterogeneous vancomycin\u2014intermediate Staphylococcus aureus","volume":"36","author":"Wongthong","year":"2020","journal-title":"World J Microbiol Biotechnol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0142","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1093\/jac\/dkaa221","article-title":"Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America","volume":"75","author":"Castro","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0143","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3855\/jidc.12799","article-title":"Investigation of heteroresistant vancomycin intermediate Staphylococcus aureus among MRSA isolates","volume":"15","author":"Gazel","year":"2021","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.jgar.2024.02.002_bib0144","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3201\/eid1807.101371","article-title":"Predicting risk for death from MRSA bacteremia","volume":"18","author":"Pastagia","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0145","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00944-20","article-title":"Vancomycin heteroresistance and clinical outcomes in bloodstream infections caused by coagulase-negative staphylococci","volume":"64","author":"Dao","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0146","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10156-004-0307-5","article-title":"Glycopeptide resistance in Staphylococcus aureus: is it a real threat?","volume":"10","author":"Gemmell","year":"2004","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0147","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10156-010-0086-0","article-title":"Clinical characteristics of vancomycin minimum inhibitory concentration of 2 \u00b5g\/mL methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia","volume":"17","author":"Takesue","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-69058-z","article-title":"Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis","volume":"10","author":"Shariati","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2024.02.002_bib0149","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"Melsen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.02.002_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-021-00967-y","article-title":"Systematic review and meta-analysis of the epidemiology of vancomycin-resistance Staphylococcus aureus isolates","volume":"10","author":"Wu","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2024.02.002_bib0151","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3201\/eid0702.010237","article-title":"Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus","volume":"7","author":"Tenover","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0152","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jinf.2009.11.011","article-title":"Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong","volume":"60","author":"Ho","year":"2010","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2024.02.002_bib0153","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/0255-0857.148837","article-title":"Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China","volume":"33","author":"Chang","year":"2015","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0154","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1378\/chest.09-2453","article-title":"Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia","volume":"138","author":"Haque","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jgar.2024.02.002_bib0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.diagmicrobio.2010.10.028","article-title":"Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Nichol","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0156","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJM199902183400701","article-title":"Emergence of vancomycin resistance in Staphylococcus aureus","volume":"340","author":"Smith","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2024.02.002_bib0157","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1128\/JCM.41.1.5-14.2003","article-title":"Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus","volume":"41","author":"Cui","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.02.002_bib0158","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1086\/346207","article-title":"Vancomycin-intermediate Staphylococcus aureus Epidemiology Study Group Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997\u20132001","volume":"36","author":"Fridkin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.002_bib0159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-019-0305-1","article-title":"Antimicrobial stewardship program (ASP): an effective implementing technique for the therapy efficiency of meropenem and vancomycin antibiotics in Iranian pediatric patients","volume":"18","author":"Rahbarimanesh","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2024.02.002_bib0160","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/1120009X.2022.2085473","article-title":"Conceptual framework of antibiotic stewardship programs in reducing ESBL-producing Enterobacteriaceae: a systematic review and meta-analysis","volume":"34","author":"Keikha","year":"2022","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0161","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/jac\/dkr066","article-title":"Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure","volume":"66","author":"Kelley","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0162","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","article-title":"Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus","volume":"50","author":"Cui","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.002_bib0163","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM199902183400704","article-title":"The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection","volume":"340","author":"Sieradzki","year":"1999","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jgar.2024.02.002_bib0164","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00157-18","article-title":"\u03b2-Lactam combinations with vancomycin show synergistic activity against vancomycin-susceptible Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA","volume":"62","author":"Tran","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:28:13Z","timestamp":1718681293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":164,"alternative-id":["S2213716524000304"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.02.002","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global distribution of heterogeneous vancomycin-intermediate Staphylococcus aureus strains (1997\u20132021): a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}